131 related articles for article (PubMed ID: 3523505)
1. Genetic polymorphism of mephenytoin metabolism.
Inaba T
Prog Clin Biol Res; 1986; 214():139-56. PubMed ID: 3523505
[No Abstract] [Full Text] [Related]
2. Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism.
Wedlund PJ; Aslanian WS; McAllister CB; Wilkinson GR; Branch RA
Clin Pharmacol Ther; 1984 Dec; 36(6):773-80. PubMed ID: 6499356
[TBL] [Abstract][Full Text] [Related]
3. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations.
Nakamura K; Goto F; Ray WA; McAllister CB; Jacqz E; Wilkinson GR; Branch RA
Clin Pharmacol Ther; 1985 Oct; 38(4):402-8. PubMed ID: 4042523
[TBL] [Abstract][Full Text] [Related]
4. Mephenytoin hydroxylase activity in human liver: inhibition by steroids.
Jurima M; Inaba T; Kalow W
Drug Metab Dispos; 1985; 13(6):746-9. PubMed ID: 2867882
[No Abstract] [Full Text] [Related]
5. S-mephenytoin 4-hydroxylase is inherited as an autosomal-recessive trait in Japanese families.
Ward SA; Goto F; Nakamura K; Jacqz E; Wilkinson GR; Branch RA
Clin Pharmacol Ther; 1987 Jul; 42(1):96-9. PubMed ID: 3595072
[TBL] [Abstract][Full Text] [Related]
6. Stereoselective mephobarbital hydroxylation cosegregates with mephenytoin hydroxylation.
Küpfer A; Branch RA
Clin Pharmacol Ther; 1985 Oct; 38(4):414-8. PubMed ID: 4042524
[TBL] [Abstract][Full Text] [Related]
7. Debrisoquin and S-mephenytoin hydroxylation phenotypes and CYP2D6 genotypes in an Estonian population.
Marandi T; Dahl ML; Kiivet RA; Rägo L; Sjöqvist F
Pharmacol Toxicol; 1996 May; 78(5):303-7. PubMed ID: 8737964
[TBL] [Abstract][Full Text] [Related]
8. S-mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquin.
Sanz EJ; Villén T; Alm C; Bertilsson L
Clin Pharmacol Ther; 1989 May; 45(5):495-9. PubMed ID: 2721104
[TBL] [Abstract][Full Text] [Related]
9. Participation of a rat liver cytochrome P-450 induced by pregnenolone 16 alpha-carbonitrile and other compounds in the 4-hydroxylation of mephenytoin.
Shimada T; Guengerich FP
Mol Pharmacol; 1985 Aug; 28(2):215-9. PubMed ID: 4022003
[TBL] [Abstract][Full Text] [Related]
10. Reproducibility over time of mephenytoin and debrisoquine hydroxylation phenotypes.
Llerena A; Valdivielso MJ; Benítez J; Bertilsson L
Pharmacol Toxicol; 1993 Jul; 73(1):46-8. PubMed ID: 8234192
[TBL] [Abstract][Full Text] [Related]
11. Characterization and inhibition of mephenytoin 4-hydroxylase activity in human liver microsomes.
Hall SD; Guengerich FP; Branch RA; Wilkinson GR
J Pharmacol Exp Ther; 1987 Jan; 240(1):216-22. PubMed ID: 2879902
[TBL] [Abstract][Full Text] [Related]
12. Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype.
Bertilsson L; Henthorn TK; Sanz E; Tybring G; Säwe J; Villén T
Clin Pharmacol Ther; 1989 Apr; 45(4):348-55. PubMed ID: 2495208
[TBL] [Abstract][Full Text] [Related]
13. Rapid screening for polymorphisms in dextromethorphan and mephenytoin metabolism.
Guttendorf RJ; Britto M; Blouin RA; Foster TS; John W; Pittman KA; Wedlund PJ
Br J Clin Pharmacol; 1990 Apr; 29(4):373-80. PubMed ID: 2328190
[TBL] [Abstract][Full Text] [Related]
14. Debrisoquine and S-mephenytoin hydroxylation polymorphisms in a Russian population living in Estonia.
Marandi T; Dahl ML; Rägo L; Kiivet R; Sjöqvist F
Eur J Clin Pharmacol; 1997; 53(3-4):257-60. PubMed ID: 9476041
[TBL] [Abstract][Full Text] [Related]
15. Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4'-hydroxylation activities in livers of Japanese and Caucasian populations.
Inoue K; Yamazaki H; Imiya K; Akasaka S; Guengerich FP; Shimada T
Pharmacogenetics; 1997 Apr; 7(2):103-13. PubMed ID: 9170147
[TBL] [Abstract][Full Text] [Related]
16. S-mephenytoin hydroxylation phenotype and CYP2C19 genotype among Ethiopians.
Persson I; Aklillu E; Rodrigues F; Bertilsson L; Ingelman-Sundberg M
Pharmacogenetics; 1996 Dec; 6(6):521-6. PubMed ID: 9014201
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man.
Küpfer A; Preisig R
Eur J Clin Pharmacol; 1984; 26(6):753-9. PubMed ID: 6489416
[TBL] [Abstract][Full Text] [Related]
18. Polymorphic metabolism of mephenytoin in man: pharmacokinetic interaction with a co-regulated substrate, mephobarbital.
Jacqz E; Hall SD; Branch RA; Wilkinson GR
Clin Pharmacol Ther; 1986 Jun; 39(6):646-53. PubMed ID: 3709029
[TBL] [Abstract][Full Text] [Related]
19. Genetic polymorphism of mephenytoin p(4')-hydroxylation: difference between Orientals and Caucasians.
Jurima M; Inaba T; Kadar D; Kalow W
Br J Clin Pharmacol; 1985 Apr; 19(4):483-7. PubMed ID: 3994895
[TBL] [Abstract][Full Text] [Related]
20. Lack of polymorphism of the conversion of losartan to its active metabolite E-3174 in extensive and poor metabolizers of debrisoquine (cytochrome P450 2D6) and mephenytoin (cytochrome P450 2C19).
Sandwall P; Lo MW; Jonzon B; Dalén P; Furtek C; Ritter M; Alván G; McCrea J; Sjöqvist F
Eur J Clin Pharmacol; 1999 Jun; 55(4):279-83. PubMed ID: 10424320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]